Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Impact of intravenous administration of anisodamine on coronary microvascular dysfunction in patients with obstructive epicardial coronary artery disease after percutaneous coronary intervention

Liang Chen¹, Bei Lei², Ying Lou¹, Lixiu Chen³, Jinqi Jiang¹

¹Department of Emergency, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, PR China; ²Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, PR China; ³Cardiac Function Room, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, PR China.

For correspondence:- Jinqi Jiang Email: jiangjinq2020@163.com

Accepted: 21 April 2022 Published: 31 May 2022

Citation: Chen L, Lei B, Lou Y, Chen L, Jiang J. Impact of intravenous administration of anisodamine on coronary microvascular dysfunction in patients with obstructive epicardial coronary artery disease after percutaneous coronary intervention. Trop J Pharm Res 2022; 21(5):1045-1053 doi: 10.4314/tjpr.v21i5.19

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To analyze intravenous administration of anisodamine’s impact on coronary microvascular dysfunction (CMD) in obstructive epicardial coronary artery disease (CAD) patients who had undergone percutaneous coronary intervention (PCI).

Methods: Enrollment of 210 patients in Shanghai Chest Hospital, Shanghai Jiaotong University with CMD was done in a randomized-controlled study. They were divided randomly into groups, viz, anisodamine (A) group and nitrate (N) group. A 14-day course of treatment was carried out in each group. 99mTc-MIBI myocardial perfusion imaging (MPI), treadmill exercise test (TET) and two-dimensional echocardiography (TDE) were performed, and the symptoms of angina pectoris were recorded before and after treatment according to the classification, frequency, and duration of angina, as defined by Canadian Cardiovascular Society (CCS).

Results: After treatment, summed stress score (SSS) and summed rest score (SRS) of MPI in group A significantly decreased after treatment (p < 0.001, respectively) and were remarkably lower than those in group N (p < 0.001, respectively). The CCS class in group A improved after treatment (p < 0.001) and was also better than in group N (p < 0.001). The frequency and duration of angina attack in group A significantly reduced after treatment (p < 0.001, respectively) and were notably lower than in group N (p < 0.001, respectively). Left ventricular ejection fraction in group A after treatment was higher than that before treatment (p = 0.046) and than that in group N (p = 0.048). Furthermore, the side effects of anisodamine were slight and tolerable.

Conclusion: Intravenous administration of anisodamine is a potentially suitable optional treatment for CMD in patients with obstructive epicardial CAD who have undergone PCI.

Keywords: Coronary microvascular dysfunction, Coronary artery disease, Percutaneous coronary intervention, Anisodamine, Intravenous administration